

1. Viral hastalıklarda dermatolojik döküntülerin önemi nedir?
2. COVID-19 enfeksiyonunun seyri sırasında görülebilen dermatolojik bulgular nelerdir?
3. COVID-19 enfeksiyonu tanısının konulmasında hastalıkta görülebilecek dermatolojik bulguların yeri nedir?
4. COVID-19 seyri sırasında görülebilen dermatolojik bulguların tedavileri nelerdir?
5. COVID-19 enfeksiyonunda kullanılan ilaçların dermatolojik yan etkileri nelerdir?

GİRİŞ VE GENEL BİLGİLER

Viral hastalıkların seyri esnasında oluşan dermatolojik bulgular oldukça iyi tanımlanmıştır ve bu bulguların genellikle tanısız veya prognostik değeri bulunmaktadır (1). COVID-19 (SARSCoV-2) enfeksiyonunun hızla pandemi şeklinde seyretmesi ile birlikte enfekte hastalarda görülen dermatolojik bulgular dünyanın her bölgesinden bildirilmeye başlanmıştır (2). Hastalık etkeninin ‘severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)’ olduğu, bronşiyal mukoza hücrelerine ve immün sistem hücrelerine tropizm gösterdiği bildirilmiştir (3).

Ayrıca virüsün, yapısal ve yapısal olmayan proteinlerinin porfirine bağlandığı, aynı zamanda ORF1ab, ORF10 ve ORF3a proteinlerinin hemoglobinin beta zincirindeki hem yapısına saldırdığı, böylece porfirin ve demiri birbirinden ayır-

¹ Uzm. Dr. Hacer KELEŞ, Samsun Eğitim ve Araştırma Hastanesi Deri ve Zührevi Hastalıkları Bölümü
dr.hacer_keles@hotmail.com

ği de unutulmamalıdır. Bununla birlikte 4 haftadan uzun süreli şiddetli perniyoz veya livedoid değişiklikleri olan hastalarda, toksik şok sendromu veya Kawasaki hastağı benzeri atipik bir tabloya sahip çocuklarda ve adolesanlarda (Multisistem enflamatuvar sendromu varlığı açısından) SARS-CoV-2 RT-PCR yapılması önerilmektedir.

KAYNAKLAR

1. Young S, Fernandez AP. Skin manifestations of COVID-19. *Cleve Clin J Med*. 2020.
2. Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: A review. *Dermatol Ther*. 2020;10:e13549.
3. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. *Zhonghua Bing Li Xue Za Zhi*. 2020;49(0):E009.
4. Liu W, Li H. Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. *ChemRxiv*. 2020; Preprint. <https://doi.org/10.26434/chemrxiv>.
5. Lan J, Song Z, BS, Xiaoping Miao X et al. Skin damage among health care workers managing coronavirus disease-2019. *J Am Acad Dermatol* 2020 May; 82 (5): 1215–1216.
6. Lin P, Zhu S, Huang Y, et al. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. *Br J Dermatol* 2020. April doi.org/10.1111/bjd.19089
7. Jiang Q, Song S, Zhou J, et al. The Prevalence, Characteristics, and Prevention Status of Skin Injury Caused by Personal Protective Equipment Among Medical Staff in Fighting COVID-19: A Multicenter, Cross-Sectional Study. *Adv Wound Care (New Rochelle)* 2020.
8. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: Lessons learned from current evidence. *J Am Acad Dermatol*. 2020 Apr 24. pii: S0190-9622 (20) 30710-6. doi: 10.1016/j.jaad.2020.04.094. [Epub ahead of print] No abstract available. Commentary. <https://doi.org/10.1016/j.jaad.2020.04.094>
9. Varkal MA, Yıldız İ, Ünüvar E. Çocuklarda ateşli döküntülü hastalıklar. *İst Tıp Fak Derg*. 2015;78(1):23-32.
10. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol*. 2020;34:e212-e213
11. Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. *J Eur Acad Dermatol Venereol* 2020;15.
12. Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones OM, Fernandez-Nieto D. Reply to “COVID-19 can present with a rash and be mistaken for Dengue”: Petechial rash in a patient with COVID-19 infection. *J Am Acad Dermatol* 2020;10.
13. Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F et al. Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy. *Acta Derm Venereol*. 2020 23;100:adv00124.
14. Hunt M, Koziatsek C. A case of COVID-19 pneumonia in a young male with full body rash as a presenting symptom. *Clin Pract Cases Emerg Med*. 2020 Mar 28. [Epub ahead of print]
15. Mahé A, Birckel E, Krieger S, et al. A distinctive skin rash associated with coronavirus disease 2019? *J Eur Acad Dermatol Venereol*. 2020 Apr 15. [Epub ahead of print]
16. Amatore F, Macagno N, Mailhe M, et al. SARS-CoV-2 infection presenting as a febrile rash. *J Eur Acad Dermatol Venereol*. 2020 Apr 24. [Epub ahead of print]
17. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases [published online ahead of print, 2020 Apr 29]. *Br J Dermatol*. 2020;10.1111/bjd.19163.

- doi:10.1111/bjd.19163
18. Marzano AV, Genovese G, Fabbrocini G, et al. Varicellalike exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. *J Am Acad Dermatol*. 2020 Apr 16. [Epub ahead of print]
 19. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020 Feb 19. [Epub ahead of print]
 20. Topal İÖ, Güngör Ş, Topal Y, Kocatürk Göncü E. Perniyo: Bir olgu bildirimi ve ayırıcı tanılarının gözden geçirilmesi. *Okmeydanı Tıp Dergisi*. 2016;32(4):230-233.
 21. Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. *Clin Exp Dermatol* 2020;17.
 22. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. 2020 May 13 doi: 10.1016/S0140- 6736 (20)31103-X [Epub ahead of print]
 23. Suowen Xu, Mingwu Chen, Jianping Weng. COVID-19 and Kawasaki disease in children *Pharmacol Res*. 2020 Sep; 159: 104951. Published online 2020 May 25. doi: 10.1016/j.phrs.2020.104951
 24. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, JanéSalas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. *Oral Dis*. 2020 May 5. doi: 10.1111/odi.13382. [Epub ahead of print]. Case reports. <https://doi.org/10.1111/odi.13382>
 25. Wu P, Liang L, Chen C, Nie S. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. *Graefes Arch Clin Exp Ophthalmol*. 2020 Apr 24. doi: 10.1007/s00417-020-04708-6. [Epub ahead of print] No abstract available. Case report. <https://doi.org/10.1007/s00417-020-04708-6>
 26. Torres-Navarro I, Abril-Pérez C, Roca-Ginés J, Sánchez-Arráez J, BotellaEstrada R. A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an issue. *J Eur Acad Dermatol Venereol*. 2020 May 26. doi: 10.1111/jdv.16664. [Epub ahead of print]. Case report. <https://doi.org/10.1111/jdv.16664>
 27. Sakaida T, Isao T, Matsubara A, Nakamura M, Morita A. Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19? *J Dermatol Sci*. 2020 May 16. doi: 10.1016/j.jdermsci. 2020.05.002. [Epub ahead of print]. Case report. <https://doi.org/10.1016/j.jdermsci. 2020.05.002>
 28. Skroza N, Bernardini N, Balduzzi V, Mambrin A, Marchesiello A, Michelini S, Tolino E, Proietti I, Di Cristofano C, Petrozza V, Potenza C. A late onset widespread skin rash in a previous COVID-19 infected patient: viral or multidrug effect? *J Eur Acad Dermatol Venereol*. 2020 May 18. doi: 10.1111/jdv.16633. [Epub ahead of print]. Case report. <https://doi.org/10.1111/jdv.16633>
 29. Litaïem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. *Dermatol Ther*. 2020 May 13: e13565. doi: 10.1111/dth.13565. [Epub ahead of print] No abstract available. Case report. <https://doi.org/10.1111/dth.13565>
 30. Sernicola A, Carnicelli G, Di Fraia M, Chello C, Furlan C, Muharremi R, Paolino G, Grieco T. "Toxic erythema" and eosinophilia associated to tocilizumab therapy in a COVID-19 patient. *J Eur Acad Dermatol Venereol*. 2020 May 9. doi: 10.1111/jdv.16620. [Epub ahead of print]. Case report. <https://doi.org/10.1111/jdv.16620>
 31. Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, Sena P. Case report. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman. *J Eur Acad Dermatol Venereol*. 2020 May 9. doi: 10.1111/jdv.16613. [Epub ahead of print].<https://doi.org/10.1111/jdv.16613>
 32. Mauro Grandolfo, Paolo Romita, Domenico Bonamonte, Gerardo Cazzato, Katharina Hansel, Luca Stingeni, Claudio Conforti, Roberta Giuffrida, Caterina Foti. Drug reaction with

eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the BÖLÜM 23 405 spotlight in the COVID_19 era. *Dermatol Ther.* 2020 May 22 : e13499. doi: 10.1111/dth.13499

33. Türsen U, Türsen B, Lotti T Cutaneous Side-Effects of the Potential COVID 19 Drugs .*Dermatol Ther* 2020 May 1;e13476. doi: 10.1111/dth. 13476. Online ahead of print.